menu

Volanesorsen goes to the EMA for marketing authorisation

“Based on the positive results from the Phase 3 program with volanesorsen, I’m encouraged that for the first time, these patients may have a new therapy that can help them achieve the triglyceride reductions they need to lessen the burden of their disease and decrease their risk for pancreatitis.” Dr. Marcello Arca, Head of the […]

“Based on the positive results from the Phase 3 program with volanesorsen, I’m encouraged that for the first time, these patients may have a new therapy that can help them achieve the triglyceride reductions they need to lessen the burden of their disease and decrease their risk for pancreatitis.” Dr. Marcello Arca, Head of the Lipid and Atherosclerosis Unit of the University Hospital Policlinico Umberto I.

 

See the press release here